September 9th 2025
Formerly known as TAR-200, gemcitabine intravesical system has received the FDA’s approval for use in patients with BCG-unresponsive NMIBC.
August 22nd 2025
IMvigor011 showed significant improvement in survival outcomes with adjuvant atezolizumab in ctDNA-positive MIBC.
August 6th 2025
New data showed a 72.2% DOR rate in patients with recurrent low-grade, intermediate-risk non–muscle-invasive bladder cancer who had a CR at 3 months.
July 21st 2025
Levels of kidney injuring molecule–1 appear to be predictive of therapeutic benefit in patients with renal cell carcinoma.
July 18th 2025
A personalized neoantigen vaccine may be effective in patients with clear cell renal cell carcinoma, shared David A. Braun, MD, PhD.
Immunotherapy: Personalized Treatment for Advanced Prostate Cancer
In April 2010, the FDA approved sipuleucel-T for patients with castration-resistant and metastatic prostate cancer, providing a new treatment that would help the body fight its own cancer.
Prostate Cancer Screening
The USPSTF releases its new recommendations for public comment.
Donna Berry on Prostate Cancer Patients' Challenges
Donna Berry on the Challenges Patients With Prostate Cancer Face
Juanita Madison Describes the Provenge Treatment Process
Juanita Madison from Seattle Cancer Care Alliance Describes the Provenge Treatment Process
Myths and Facts About Kidney Cancer
March was National Kidney Month, so here is an opportunity to test your knowledge about kidney cancer.
Resources for People Living with Kidney Cancer
Help kidney cancer patients by being aware of available resources and support services
Behavioral Therapy Alleviates Prostatectomy-Induced Incontinence
Behavioral therapy reduced episodes of urinary incontinence following radical prostatectomy by 55% in a study of 208 men with incontinence persisting %u22651 year following prostatectomy.
Lutetium Lu 177 Dotatate Brings Partial Response in Metastatic BP-NETs
Safety Management With Amivantamab Plus Lazertinib in NSCLC
Tepotinib Shows Manageable Safety in MET Exon 14+ NSCLC
Adverse Events of Menin Inhibitors in AML: What Nurses Should Know